Biopharma · FDA Approvals · Stock
Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a pr…
Assets on file: AT177
Dated catalysts for AZR, including recently decided ones.
Every first-hand event for AZR, newest first.
Azora Therapeutics Reiterates AT177 IND Submission and Phase 1a Initiation on Track for H1 2027
This quarterly earnings release and business update restates that IND-enabling studies for AT177 (colon-targeted AhR agonist) are continuing and that submission of the IND plus initiation of the Phase 1a SAD/MAD trial remain on track for the first half of 2027. The document also notes completed GLP toxicology studies and pre-IND FDA feedback.
Companies in the same sector closest to AZR in market value.